Renal cell carcinoma · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`None`

ID	`IND-HPRC-CARRIER-INTENSIFIED`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-RCC`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB — v0.2-B confirmed-carrier intensified track (HPRC / MET). Sibling — IND-HPRC-CARRIER-SURVEILLANCE. §15.2 C4 ≥2-tracks invariant.

Used By

Indication

IND-HPRC-CARRIER-SURVEILLANCE - IND-HPRC-CARRIER-SURVEILLANCE

Red flag

RF-HPRC-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in the MET proto-oncogene — Her...